17-9-4-4 ⓔ文献
骨髄異形成症候群の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ：骨髄異形成症候群診療の参照ガイド 平成28年度改訂版，2016．http://zoketsushogaihan.com/file/guideline_H28/04.pdf
Bennett JM, Catovsky D, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982; 51: 189–199.
Swerdlow SH, Campo E, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, International Agency for Research on Cancer, 2017.
Greenberg P, Cox C, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997; 89: 2079–2088.
Greenberg PL, Tuechler H, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 2012; 120: 2454–2465.
Bannon SA, DiNardo CD: Hereditary predispositions to myelodysplastic Syndrome. Int J Mol Sci, 2016; 17: 838.
Kennedy AL, Shimamura A: Genetic predisposition to MDS: clinical features and clonal evolution. Blood, 2019; 133: 1071–1085.
McNerney ME, Godley LA, et al: Therapy–related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer, 2017; 17: 513–527.
Chung SS, Park CY: Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Adv, 2017; 1: 2572–2578.
Chihara D, Ito H, et al: Incidence of myelodysplastic syndrome in Japan. J Epidemiol, 2014; 24: 469–473.
Greenberg PL, Stone RM, et al: Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017; 15: 60–87.
Ogawa S: Genetics of MDS. Blood, 2019; 133: 1049–1059.
Yoshida K, Sanada M, et al: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 2011; 478: 64–69.
Haase D, Stevenson KE, et al: TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019; 33: 1747–1758.
Jaiswal S, Fontanillas P, et al: Age–related clonal hematopoiesis associated with adverse outcomes. N Engl J Med, 2014; 371: 2488–2498.
da Silva–Coelho P, Kroeze LI, et al: Clonal evolution in myelodysplastic syndromes. Nat Commun, 2017; 8: 15099.
Steensma DP, Bejar R, et al: Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 2015; 126: 9–16.
Mattiucci D, Maurizi G, et al: Aging– and senescence–associated changes of mesenchymal stromal cells in myelodysplastic syndromes. Cell Transplant, 2018; 27: 754–764.
Wolach O, Stone R: Autoimmunity and inflammation in myelodysplastic syndromes. Acta Haematol, 2016; 136: 108–117.
Masutani R, Ikemoto T, et al: Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome. Health Sci Rep, 2018; 1: e50.
Wang H, Chuhjo T, et al: Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria–type cells in bone marrow failure syndrome. Blood, 2002; 100: 3897–3902.
不応性貧血 (骨髄異形成症候群) の形態学的診断基準作成のためのワーキンググループ：不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス，2008．http://www.jshem.or.jp/uploads/files/former/MDS.pdf
厚生労働省科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究班：輸血後鉄過剰症の診療ガイド，2008．http://www.jichi.ac.jp/zoketsushogaihan/tetsufinal.pdf
日本血液学会編：造血器腫瘍診療ガイドライン 2018年版．金原出版，2018.
Harada H, Watanabe M, et al: Lenalidomide is active in Japanese patients with symptomatic anemia in low–or intermediate–1 risk myelodysplastic syndromes with a deletion 5q abnormality. Int J Hematol, 2009; 90: 353–360.
Park S, Fenaux P, et al: Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta–analysis. Br J Haematol, 2016; 174: 730–747.
Ishikawa T, Tohyama K, et al: A prospective study of cyclosporine A treatment of patients with low–risk myelodysplastic syndrome: presence of CD55 (-) CD59 (-) blood cells predicts platelet response. Int J Hematol, 2007; 86: 150–157.
NCCN: Myelodysplastic syndromes: NCCN evidence blocks, ed version 1.2020. 2019. https://www.nccn.org/professionals/physician_gls/PDF/mds.pdf.